[English] 日本語
Yorodumi- EMDB-9829: The cryo-EM structure of HAV bound to a neutralizing antibody-F7 -
+
Open data
-
Basic information
| Entry | Database: EMDB / ID: EMD-9829 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Title | The cryo-EM structure of HAV bound to a neutralizing antibody-F7 | ||||||||||||
Map data | map of F7_Fab_HAV complex | ||||||||||||
Sample |
| ||||||||||||
Keywords | Icosahedral symmetry / neutralizing antibody / HAV / complex / VIRUS | ||||||||||||
| Function / homology | Function and homology informationhost cell mitochondrial outer membrane / symbiont-mediated suppression of host cytoplasmic pattern recognition receptor signaling pathway via inhibition of MAVS activity / ribonucleoside triphosphate phosphatase activity / picornain 3C / T=pseudo3 icosahedral viral capsid / host multivesicular body / host cell cytoplasmic vesicle membrane / nucleoside-triphosphate phosphatase / channel activity / monoatomic ion transmembrane transport ...host cell mitochondrial outer membrane / symbiont-mediated suppression of host cytoplasmic pattern recognition receptor signaling pathway via inhibition of MAVS activity / ribonucleoside triphosphate phosphatase activity / picornain 3C / T=pseudo3 icosahedral viral capsid / host multivesicular body / host cell cytoplasmic vesicle membrane / nucleoside-triphosphate phosphatase / channel activity / monoatomic ion transmembrane transport / RNA helicase activity / RNA-directed RNA polymerase / cysteine-type endopeptidase activity / viral RNA genome replication / RNA-directed RNA polymerase activity / DNA-templated transcription / symbiont entry into host cell / virion attachment to host cell / structural molecule activity / proteolysis / RNA binding / ATP binding / membrane Similarity search - Function | ||||||||||||
| Biological species | ![]() Human hepatitis A virus Hu/Australia/HM175/1976 / Human hepatitis A virus | ||||||||||||
| Method | single particle reconstruction / cryo EM / Resolution: 3.05 Å | ||||||||||||
Authors | Cao L / Liu P | ||||||||||||
| Funding support | China, 3 items
| ||||||||||||
Citation | Journal: PLoS Biol / Year: 2019Title: Structural basis for neutralization of hepatitis A virus informs a rational design of highly potent inhibitors. Authors: Lei Cao / Pi Liu / Pan Yang / Qiang Gao / Hong Li / Yao Sun / Ling Zhu / Jianping Lin / Dan Su / Zihe Rao / Xiangxi Wang / ![]() Abstract: Hepatitis A virus (HAV), an enigmatic and ancient pathogen, is a major causative agent of acute viral hepatitis worldwide. Although there are effective vaccines, antivirals against HAV infection are ...Hepatitis A virus (HAV), an enigmatic and ancient pathogen, is a major causative agent of acute viral hepatitis worldwide. Although there are effective vaccines, antivirals against HAV infection are still required, especially during fulminant hepatitis outbreaks. A more in-depth understanding of the antigenic characteristics of HAV and the mechanisms of neutralization could aid in the development of rationally designed antiviral drugs targeting HAV. In this paper, 4 new antibodies-F4, F6, F7, and F9-are reported that potently neutralize HAV at 50% neutralizing concentration values (neut50) ranging from 0.1 nM to 0.85 nM. High-resolution cryo-electron microscopy (cryo-EM) structures of HAV bound to F4, F6, F7, and F9, together with results of our previous studies on R10 fragment of antigen binding (Fab)-HAV complex, shed light on the locations and nature of the epitopes recognized by the 5 neutralizing monoclonal antibodies (NAbs). All the epitopes locate within the same patch and are highly conserved. The key structure-activity correlates based on the antigenic sites have been established. Based on the structural data of the single conserved antigenic site and key structure-activity correlates, one promising drug candidate named golvatinib was identified by in silico docking studies. Cell-based antiviral assays confirmed that golvatinib is capable of blocking HAV infection effectively with a 50% inhibitory concentration (IC50) of approximately 1 μM. These results suggest that the single conserved antigenic site from complete HAV capsid is a good antiviral target and that golvatinib could function as a lead compound for anti-HAV drug development. | ||||||||||||
| History |
|
-
Structure visualization
| Movie |
Movie viewer |
|---|---|
| Structure viewer | EM map: SurfView Molmil Jmol/JSmol |
| Supplemental images |
-
Downloads & links
-EMDB archive
| Map data | emd_9829.map.gz | 395.5 MB | EMDB map data format | |
|---|---|---|---|---|
| Header (meta data) | emd-9829-v30.xml emd-9829.xml | 16.8 KB 16.8 KB | Display Display | EMDB header |
| Images | emd_9829.png | 234.2 KB | ||
| Filedesc metadata | emd-9829.cif.gz | 6.6 KB | ||
| Archive directory | http://ftp.pdbj.org/pub/emdb/structures/EMD-9829 ftp://ftp.pdbj.org/pub/emdb/structures/EMD-9829 | HTTPS FTP |
-Validation report
| Summary document | emd_9829_validation.pdf.gz | 668.5 KB | Display | EMDB validaton report |
|---|---|---|---|---|
| Full document | emd_9829_full_validation.pdf.gz | 668 KB | Display | |
| Data in XML | emd_9829_validation.xml.gz | 7.6 KB | Display | |
| Data in CIF | emd_9829_validation.cif.gz | 8.9 KB | Display | |
| Arichive directory | https://ftp.pdbj.org/pub/emdb/validation_reports/EMD-9829 ftp://ftp.pdbj.org/pub/emdb/validation_reports/EMD-9829 | HTTPS FTP |
-Related structure data
| Related structure data | ![]() 6jhsMC ![]() 9827C ![]() 9828C ![]() 9830C ![]() 6jhqC ![]() 6jhrC ![]() 6jhtC M: atomic model generated by this map C: citing same article ( |
|---|---|
| Similar structure data |
-
Links
| EMDB pages | EMDB (EBI/PDBe) / EMDataResource |
|---|---|
| Related items in Molecule of the Month |
-
Map
| File | Download / File: emd_9829.map.gz / Format: CCP4 / Size: 421.9 MB / Type: IMAGE STORED AS FLOATING POINT NUMBER (4 BYTES) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annotation | map of F7_Fab_HAV complex | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Projections & slices | Image control
Images are generated by Spider. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Voxel size | X=Y=Z: 1.35 Å | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Density |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Symmetry | Space group: 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Details | EMDB XML:
CCP4 map header:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
-Supplemental data
-
Sample components
-Entire : Human hepatitis A virus and antibody-F7
| Entire | Name: Human hepatitis A virus and antibody-F7 |
|---|---|
| Components |
|
-Supramolecule #1: Human hepatitis A virus and antibody-F7
| Supramolecule | Name: Human hepatitis A virus and antibody-F7 / type: complex / ID: 1 / Parent: 0 / Macromolecule list: all |
|---|
-Supramolecule #3: antibody-F7
| Supramolecule | Name: antibody-F7 / type: complex / ID: 3 / Parent: 1 / Macromolecule list: #4-#5 |
|---|---|
| Source (natural) | Organism: ![]() |
-Supramolecule #2: Human hepatitis A virus
| Supramolecule | Name: Human hepatitis A virus / type: virus / ID: 2 / Parent: 1 / Macromolecule list: #1-#3 / NCBI-ID: 208726 / Sci species name: Human hepatitis A virus / Virus type: VIRION / Virus isolate: STRAIN / Virus enveloped: No / Virus empty: No |
|---|
-Macromolecule #1: VP1
| Macromolecule | Name: VP1 / type: protein_or_peptide / ID: 1 / Number of copies: 1 / Enantiomer: LEVO |
|---|---|
| Source (natural) | Organism: Human hepatitis A virus Hu/Australia/HM175/1976 |
| Molecular weight | Theoretical: 30.820629 KDa |
| Sequence | String: VGDDSGGFST TVSTEQNVPD PQVGITTMRD LKGKANRGKM DVSGVQAPVG AITTIEDPVL AKKVPETFPE LKPGESRHTS DHMSIYKFM GRSHFLCTFT FNSNNKEYTF PITLSSTSNP PHGLPSTLRW FFNLFQLYRG PLDLTIIITG ATDVDGMAWF T PVGLAVDT ...String: VGDDSGGFST TVSTEQNVPD PQVGITTMRD LKGKANRGKM DVSGVQAPVG AITTIEDPVL AKKVPETFPE LKPGESRHTS DHMSIYKFM GRSHFLCTFT FNSNNKEYTF PITLSSTSNP PHGLPSTLRW FFNLFQLYRG PLDLTIIITG ATDVDGMAWF T PVGLAVDT PWVEKESALQ IDYKTALGAV RFNTRRTGNI QIRLPWYSYL YAVSGALDGL GDKTDSTFGL VSIQIANYNH SD EYLSFSC YLSVTEQSEF YFPRAPLNSN AMLSTESMMS R |
-Macromolecule #2: VP2
| Macromolecule | Name: VP2 / type: protein_or_peptide / ID: 2 / Number of copies: 1 / Enantiomer: LEVO |
|---|---|
| Source (natural) | Organism: Human hepatitis A virus Hu/Australia/HM175/1976 |
| Molecular weight | Theoretical: 24.898172 KDa |
| Sequence | String: DIEEEQMIQS VDRTAVTGAS YFTSVDQSSV HTAEVGSHQI EPLKTSVDKP GSKKTQGEKF FLIHSARWLT THALFHEVAK LDVVKLLYN EQFAVQGLLR YHTYARFGIE IQVQINPTPF QQGGLICAMV PGDQSYGSIA SLTVYPHGLL NCNINNVVRI K VPFIYTRG ...String: DIEEEQMIQS VDRTAVTGAS YFTSVDQSSV HTAEVGSHQI EPLKTSVDKP GSKKTQGEKF FLIHSARWLT THALFHEVAK LDVVKLLYN EQFAVQGLLR YHTYARFGIE IQVQINPTPF QQGGLICAMV PGDQSYGSIA SLTVYPHGLL NCNINNVVRI K VPFIYTRG AYHFKDPQYP VWELTIRVWS ELNIGTGTSA YTSLNVLARF TDLELHGLTP LSTQ |
-Macromolecule #3: VP3
| Macromolecule | Name: VP3 / type: protein_or_peptide / ID: 3 / Number of copies: 1 / Enantiomer: LEVO |
|---|---|
| Source (natural) | Organism: Human hepatitis A virus Hu/Australia/HM175/1976 |
| Molecular weight | Theoretical: 27.835693 KDa |
| Sequence | String: MMRNETRVST TENVVNLSNY EDARAKMSFA LDQEDWKSDP SQGGGIKITH FTTWTSIPTL AAQFPFNASD SVGQQIKVIP VDPYFFQMT NTNPDQKCIT ALASICQMFC FWRGDLVFDF QVFPTKYHSG RLLFCFVPGN ELIDVTGITL KQATTAPCAV M DIAGVQST ...String: MMRNETRVST TENVVNLSNY EDARAKMSFA LDQEDWKSDP SQGGGIKITH FTTWTSIPTL AAQFPFNASD SVGQQIKVIP VDPYFFQMT NTNPDQKCIT ALASICQMFC FWRGDLVFDF QVFPTKYHSG RLLFCFVPGN ELIDVTGITL KQATTAPCAV M DIAGVQST LRFRVPWISD TPYRVNRYTK EAHQKGEYTA IGKLIVYCYN RLTSPSNVAH HVRVNVYLSA INLECFAPLY HA MDVTTQ |
-Macromolecule #4: FAB Light Chain
| Macromolecule | Name: FAB Light Chain / type: protein_or_peptide / ID: 4 / Number of copies: 1 / Enantiomer: LEVO |
|---|---|
| Source (natural) | Organism: ![]() |
| Molecular weight | Theoretical: 23.437805 KDa |
| Sequence | String: DIVLTQSPAI MSASPGEKVT MTCSAASSVS YIHWYQQKSG TSPKRWIYDT SRLAFGVPTR FSGSGSGTSY SLTISSMEAE DAATYYCQQ WSTNPYTFGG GTKLEIKRAD AAPTVSIFPP SSEQLTSGGA SVVCFLNNFY PKDINVKWKI DGSERQNGVL N SWTDQDSK ...String: DIVLTQSPAI MSASPGEKVT MTCSAASSVS YIHWYQQKSG TSPKRWIYDT SRLAFGVPTR FSGSGSGTSY SLTISSMEAE DAATYYCQQ WSTNPYTFGG GTKLEIKRAD AAPTVSIFPP SSEQLTSGGA SVVCFLNNFY PKDINVKWKI DGSERQNGVL N SWTDQDSK DSTYSMSSTL TLTKDEYERH NSYTCEATHK TSTSPIVKSF NRNEC |
-Macromolecule #5: FAB Heavy Chain
| Macromolecule | Name: FAB Heavy Chain / type: protein_or_peptide / ID: 5 / Number of copies: 1 / Enantiomer: LEVO |
|---|---|
| Source (natural) | Organism: ![]() |
| Molecular weight | Theoretical: 23.796752 KDa |
| Sequence | String: EVKLVESGGG LVKPGGSLKL SCAASIHTFN CYGMSWVRQT PEKGLEWVAT IDAASSYTYY PDSVKGRFTI SRDNAKNTLY LQMSSLRSG DTAMYYCARR DNTTAQYYFD YWGQGTTLTV SSPKTTPPSV YPLAPASAST AASMVTLGCL VKGYFPEPVT V TWNSGSLS ...String: EVKLVESGGG LVKPGGSLKL SCAASIHTFN CYGMSWVRQT PEKGLEWVAT IDAASSYTYY PDSVKGRFTI SRDNAKNTLY LQMSSLRSG DTAMYYCARR DNTTAQYYFD YWGQGTTLTV SSPKTTPPSV YPLAPASAST AASMVTLGCL VKGYFPEPVT V TWNSGSLS SGVHTFPAVL QSDLYTLSSS VTVPSSTWPS ETVTCNVAHP ASSTKVDKKI VPR |
-Experimental details
-Structure determination
| Method | cryo EM |
|---|---|
Processing | single particle reconstruction |
| Aggregation state | particle |
-
Sample preparation
| Buffer | pH: 7 |
|---|---|
| Vitrification | Cryogen name: ETHANE |
-
Electron microscopy
| Microscope | FEI TITAN KRIOS |
|---|---|
| Image recording | Film or detector model: GATAN K2 BASE (4k x 4k) / Average electron dose: 1.3 e/Å2 |
| Electron beam | Acceleration voltage: 300 kV / Electron source: FIELD EMISSION GUN |
| Electron optics | Illumination mode: FLOOD BEAM / Imaging mode: BRIGHT FIELD |
| Experimental equipment | ![]() Model: Titan Krios / Image courtesy: FEI Company |
Movie
Controller
About Yorodumi


Human hepatitis A virus
Keywords
Authors
China, 3 items
Citation
UCSF Chimera


















Z (Sec.)
Y (Row.)
X (Col.)





















Processing

